BE2014C071I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C071I2
BE2014C071I2 BE2014C071C BE2014C071C BE2014C071I2 BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2 BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 C BE2014C071 C BE 2014C071C BE 2014C071 I2 BE2014C071 I2 BE 2014C071I2
Authority
BE
Belgium
Application number
BE2014C071C
Other languages
French (fr)
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C071(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BE2014C071I2 publication Critical patent/BE2014C071I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2014C071C 2004-06-11 2014-11-28 BE2014C071I2 (en, 2012)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004174770 2004-06-11
JP2004327111 2004-11-10
US63059604P 2004-11-23 2004-11-23
US11/150,792 US7378423B2 (en) 2004-06-11 2005-06-10 Pyrimidine compound and medical use thereof

Publications (1)

Publication Number Publication Date
BE2014C071I2 true BE2014C071I2 (en, 2012) 2024-10-08

Family

ID=35600249

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C071C BE2014C071I2 (en, 2012) 2004-06-11 2014-11-28

Country Status (2)

Country Link
US (8) US7378423B2 (en, 2012)
BE (1) BE2014C071I2 (en, 2012)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia PROCEDURE BASED ON TYPE 1 RYANODIN RECEPTOR
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
PT1859793E (pt) * 2005-02-28 2011-07-05 Eisai R&D Man Co Ltd Uso combinado inovador de um composto de sulfonamida no tratamento oncológico
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20080242648A1 (en) * 2006-11-10 2008-10-02 Syndax Pharmaceuticals, Inc., A California Corporation COMBINATION OF ERa+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
CN101809024A (zh) * 2007-07-16 2010-08-18 铂雅制药公司 吡铂的口服制剂
WO2009015237A1 (en) * 2007-07-23 2009-01-29 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
WO2009049018A1 (en) * 2007-10-10 2009-04-16 Syndax Pharmaceuticals, Inc. Novel compounds and methods of using them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
RU2508110C2 (ru) * 2008-07-11 2014-02-27 Новартис Аг КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek
JP5743897B2 (ja) 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
US8647067B2 (en) * 2008-12-09 2014-02-11 General Electric Company Banked platform turbine blade
US9084781B2 (en) 2008-12-10 2015-07-21 Novartis Ag MEK mutations conferring resistance to MEK inhibitors
US8841447B2 (en) * 2009-03-26 2014-09-23 Mapi Pharma Ltd. Process for the preparation of alogliptin
MX2012003547A (es) * 2009-09-23 2012-04-30 Glaxosmithkline Llc Combinacion.
EP2480084B1 (en) * 2009-09-23 2014-11-12 GlaxoSmithKline LLC Pharmaceutical combination
KR20120099217A (ko) 2009-09-28 2012-09-07 글락소스미스클라인 엘엘씨 조합물
HRP20221304T1 (hr) 2009-10-16 2022-12-23 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
WO2011062930A1 (en) * 2009-11-17 2011-05-26 Glaxosmithkline Llc Combination
CN103002894B (zh) 2010-02-25 2016-04-06 达纳－法伯癌症研究所公司 对braf抑制剂具有抗性的braf突变
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
BR112012024380A2 (pt) 2010-03-25 2015-09-15 Glaxosmithkline Llc compostos químicos
US9180129B2 (en) * 2010-05-21 2015-11-10 Novartis Ag Combination of lapatinib and trametinib
WO2012027438A1 (en) 2010-08-26 2012-03-01 Glaxosmithkline Llc Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
US20130231346A1 (en) * 2010-11-17 2013-09-05 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
EP2654755B1 (en) 2010-12-20 2016-08-17 Novartis AG Combination therapy comprising Gemcitabine for the treatment of pancreatic cancer
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CN103764144B (zh) 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CN107698585A (zh) 2012-03-14 2018-02-16 鲁宾有限公司 杂环基化合物
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
MX367970B (es) 2012-08-17 2019-09-11 Hoffmann La Roche Tratamientos de combinación para melanoma que comprenden la administración de cobimetinib y vemurafinib.
WO2014066606A2 (en) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combination
IL300664A (en) * 2012-11-30 2023-04-01 Novartis Ag Innovative pharmaceutical composition
JP2016504409A (ja) 2013-01-09 2016-02-12 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 組合せ
WO2014109858A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
UY35587A (es) 2013-05-28 2014-12-31 Glaxosmithkline Ip No 2 Ltd Método de tratamiento del cáncer
SG11201509742QA (en) 2013-06-03 2015-12-30 Novartis Ag Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015056180A1 (en) 2013-10-15 2015-04-23 Glaxosmithkline Intellectual Property (No.2) Limited Indoline derivatives as inhibitors of perk
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
AU2014362995A1 (en) 2013-12-12 2016-05-26 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
ES2822125T3 (es) 2013-12-28 2021-04-29 Guardant Health Inc Métodos y sistemas para detectar variantes genéticas
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
EP2913048A1 (en) 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016055935A1 (en) 2014-10-06 2016-04-14 Glaxosmithkline Intellectual Property (No.2) Limited Combination of lysine-specific demethylase 1 inhibitor and thrombopoietin agonist
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
US20190365741A1 (en) 2015-08-28 2019-12-05 Novartis Ag Combinations of the cdk4/6 inhibitor lee011 and the mek1/2 inhibitor trametinib, optionally further comprising the pi3k inhibitor byl719 to treat cancer
AU2016350700A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding PD-1 and TIM-3 and their uses
US10861357B2 (en) * 2015-11-13 2020-12-08 Nike, Inc. Athletic bib
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
KR101796684B1 (ko) * 2016-05-19 2017-11-10 건국대학교 산학협력단 케라틴 8 인산화 억제제를 포함하는 황반변성 예방 또는 치료용 약학 조성물 및 황반변성 치료제의 스크리닝 방법
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
AU2019372121A1 (en) * 2018-10-30 2021-05-27 Nuvation Bio Inc. Heterocyclic compounds as BET inhibitors
IL283487B2 (en) 2018-11-30 2024-07-01 Glaxosmithkline Ip Dev Ltd Compounds useful in hiv therapy
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
US12221440B2 (en) * 2019-02-06 2025-02-11 Aurobindo Pharma Ltd Process for the preparation of trametinib acetic acid solvate
KR102677015B1 (ko) 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
AU2020323687A1 (en) * 2019-07-30 2022-02-17 Edvince Ab MEK inhibitor for treatment of stroke
AU2020326612A1 (en) 2019-08-02 2022-03-17 Onehealthcompany, Inc. Treatment of canine cancers
US12268692B2 (en) 2020-04-10 2025-04-08 Postsurgical Therapeutics, Inc. Combinatorial targeted therapy methods
WO2021263188A1 (en) * 2020-06-25 2021-12-30 Icahn School Of Medicine At Mount Sinai Live cell engagement assay
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3139432A (en) 1963-06-24 1964-06-30 Mead Johnson & Co Pyrido [2, 3-d] pyrimidine-2, 4, 5, 7-tetraones
DE4035479A1 (de) 1990-11-08 1992-05-14 Basf Ag Substituierte pyrido (2,3-d)pyrimidin-2,4(1h,3h)-dione
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
HUP0104693A3 (en) 1998-12-16 2003-12-29 Warner Lambert Co Treatment of arthritis with mek inhibitors
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
DE69924641D1 (de) 1999-01-07 2005-05-12 Warner Lambert Company Llc Mor Behandlung von asthma anhand von mek-inhibitoren
DE60005688T2 (de) 1999-07-16 2004-04-29 Warner-Lambert Co. Llc Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer
UA72612C2 (en) 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos
WO2002006520A1 (fr) 2000-07-19 2002-01-24 Chugai Seiyaku Kabushiki Kaisha Methode de criblage de compose regulant la transduction de signaux mek/erk et utilisation medicale dudit compose
EP1391211A1 (en) 2001-04-27 2004-02-25 Chugai Seiyaku Kabushiki Kaisha Chondrogenesis promoters
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
CN101906104B (zh) 2002-01-22 2013-06-05 沃尼尔·朗伯有限责任公司 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof

Also Published As

Publication number Publication date
US20100240613A1 (en) 2010-09-23
US20200109139A1 (en) 2020-04-09
US20170029418A1 (en) 2017-02-02
US8835443B2 (en) 2014-09-16
US7378423B2 (en) 2008-05-27
US20180273531A1 (en) 2018-09-27
US20220380362A1 (en) 2022-12-01
US20150183812A1 (en) 2015-07-02
US20060014768A1 (en) 2006-01-19
US20080312228A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
BE2024C508I2 (en, 2012)
BE2022C549I2 (en, 2012)
BE2023C542I2 (en, 2012)
BE2021C001I2 (en, 2012)
BE2020C513I2 (en, 2012)
BE2020C517I2 (en, 2012)
BE2019C540I2 (en, 2012)
BE2019C523I2 (en, 2012)
BE2019C506I2 (en, 2012)
BE2019C548I2 (en, 2012)
BE2018C045I2 (en, 2012)
BE2017C063I2 (en, 2012)
BE2020C525I2 (en, 2012)
BE2017C027I2 (en, 2012)
BE2017C023I2 (en, 2012)
BE2017C002I2 (en, 2012)
BE2016C067I2 (en, 2012)
BE2015C066I2 (en, 2012)
BE2013C071I2 (en, 2012)
BE2013C021I2 (en, 2012)
BE2012C025I2 (en, 2012)
BE2019C535I2 (en, 2012)
JP2005199058A5 (en, 2012)
JP2005273771A5 (en, 2012)
BE2016C042I2 (en, 2012)